NICHD spermicide trial receives FDA advisory committee endorsement.
This article was originally published in The Tan Sheet
Executive Summary
NICHD SPERMICIDE TRIAL ENDORSED BY FDA ADVISORY COMMITTEES at a Nov. 22 joint meeting of FDA's Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees in Gaithersburg, Md. The joint committee overwhelmingly agreed that more efficacy data is needed for marketed OTC vaginal spermicides and lauded the National Institute of Child Health & Human Development's proposed four-year, 1,200-subject study of several marketed nonoxynol-9-containing vaginal spermicides as a source of much-needed information on efficacy in pregnancy prevention.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning